Oramed Pharmaceuticals (NASDAQ:ORMP) COO Sells $611,020.00 in Stock

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) COO Joshua Hexter sold 137,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.46, for a total transaction of $611,020.00. Following the sale, the chief operating officer owned 1,023,384 shares of the company’s stock, valued at $4,564,292.64. The trade was a 11.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Oramed Pharmaceuticals Trading Down 0.2%

Shares of NASDAQ:ORMP traded down $0.01 during midday trading on Thursday, hitting $4.60. The company had a trading volume of 360,793 shares, compared to its average volume of 241,456. Oramed Pharmaceuticals Inc. has a 12 month low of $1.98 and a 12 month high of $5.19. The firm has a fifty day simple moving average of $4.08 and a 200 day simple moving average of $3.62. The stock has a market cap of $188.26 million, a price-to-earnings ratio of 1.78 and a beta of 1.21.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 11th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company has an average rating of “Hold”.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. SB Capital Management Inc acquired a new stake in Oramed Pharmaceuticals in the 4th quarter valued at approximately $5,415,000. Marshall Wace LLP acquired a new position in Oramed Pharmaceuticals during the 4th quarter worth approximately $738,000. Ritholtz Wealth Management acquired a new position in Oramed Pharmaceuticals during the 1st quarter worth approximately $529,000. Hillsdale Investment Management Inc. bought a new position in shares of Oramed Pharmaceuticals during the 1st quarter worth approximately $331,000. Finally, HRT Financial LP acquired a new stake in shares of Oramed Pharmaceuticals in the fourth quarter valued at approximately $131,000. Institutional investors and hedge funds own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.